{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:33:28Z","timestamp":1791113608563,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:00:00Z","timestamp":1424217600000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.jacc.2013.09.056","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T18:46:40Z","timestamp":1383158800000},"page":"528-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients"],"prefix":"10.1016","volume":"63","author":[{"given":"Yoshihiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Arihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yakushigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsumi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.09.056_bib1","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0272-6386(99)80018-3","article-title":"VI. Causes of death in ESRD","volume":"34","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2013.09.056_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ki.1996.403","article-title":"ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States","volume":"50","author":"Marcelli","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.09.056_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention (MOSES): principal results of a prospective randomized controlled study","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2013.09.056_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.09.056_bib6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.ki.5001657","article-title":"Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies","volume":"70","author":"Zannad","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.09.056_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2013.09.056_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib11","doi-asserted-by":"crossref","first-page":"R944","DOI":"10.1152\/ajpregu.2001.281.3.R944","article-title":"Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats","volume":"281","author":"Dorrance","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.jacc.2013.09.056_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1210\/en.2008-0808","article-title":"11beta-hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia","volume":"150","author":"Osmond","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2013.09.056_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000210553","article-title":"Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients","volume":"114","author":"Matsumoto","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2013.09.056_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2013.09.056_bib15","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic haemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2013.09.056_bib16","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","article-title":"Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study","volume":"65","author":"Cheung","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.09.056_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1744-9987.2012.01143.x","article-title":"An overview of regular dialysis treatment in Japan (as of 31 December 2010)","volume":"16","author":"Nakai","year":"2012","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacc.2013.09.056_bib18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?","volume":"3","author":"Stenvinkel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2013.09.056_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000210552","article-title":"The role of aldosterone blockade in end-stage renal disease","volume":"114","author":"Pitt","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2013.09.056_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.09.056_bib21","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1681\/ASN.2007020184","article-title":"Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study","volume":"18","author":"Cano","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2013.09.056_bib22","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa021583","article-title":"Effect of dialysis dose and membrane flux in maintenance hemodialysis","volume":"347","author":"Eknoyan","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib23","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1210\/en.2002-220120","article-title":"Selective aldosterone blockade prevents angiotensin II\/salt-induced vascular inflammation in the rat heart","volume":"143","author":"Rocha","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2013.09.056_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1523-1755.2003.00707.x","article-title":"Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity","volume":"63","author":"Feria","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2013.09.056_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.09.056_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2003.10.012","article-title":"Vascular synthesis of aldosterone: role in hypertension","volume":"217","author":"Takeda","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jacc.2013.09.056_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","article-title":"Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction","volume":"58","author":"Schafer","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2013.09.056_bib28","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","article-title":"Dose-related cardiovascular effects of spironolactone","volume":"71","author":"Schohn","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.09.056_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0008-6363(97)00097-7","article-title":"Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion","volume":"35","author":"Sun","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2013.09.056_bib30","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2013.09.056_bib31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/01.STR.0000226399.13528.0a","article-title":"Common carotid artery intima-media thickness and the risk of stroke recurrence","volume":"37","author":"Tsivgoulis","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2013.09.056_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults","volume":"340","author":"O'Leary","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.09.056_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.09.056_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1525-139X.2008.00455.x","article-title":"Sudden cardiac death and dialysis patients","volume":"21","author":"Herzog","year":"2008","journal-title":"Semin Dial"},{"key":"10.1016\/j.jacc.2013.09.056_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1527-5299.2005.03722.x","article-title":"Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure","volume":"11","author":"Yoshida","year":"2005","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.jacc.2013.09.056_bib36","first-page":"745","article-title":"Enhanced expression of mineralocorticoid receptors in the heart after the myocardial infarct in rats","volume":"58","author":"Milik","year":"2007","journal-title":"J\u00a0Physiol Pharmacol"},{"key":"10.1016\/j.jacc.2013.09.056_bib37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjcard.2006.03.028","article-title":"Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension","volume":"98","author":"Sukhija","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.09.056_bib38","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1253\/circj.CJ-08-1065","article-title":"Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes","volume":"73","author":"Suzuki","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2013.09.056_bib39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000085691","article-title":"Electrophysiological response to dialysis: the role of dialysate potassium content and profiling","volume":"149","author":"Santoro","year":"2005","journal-title":"Contrib Nephrol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713057380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713057380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:06:27Z","timestamp":1760015187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713057380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0735109713057380"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.056","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718164016.793494330","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718164016.793494146","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.09.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}